Final data from S9346/INT-0162 published in NEJM this week

Last June, at the annual meeting of the American Society for Clinical Oncology, Hussain and colleagues presented data from the S9346/INT-0162 trial of continuous vs. intermittent androgen deprivation therapy in men with androgen-sensitive, metastatic prostate cancer. … READ MORE …

Four major advances in treatment of late stage prostate cancer in 2012

In a new paper in the Journal of Clinical Oncology, the American Society for Clinical Oncology (ASCO) has identified four significant advances in the treatment of late stage prostate cancer during 2012. … READ MORE …

IADT: the still unanswered questions and choices that must be made

About 18 months ago, at the 2011 Genitourinary Cancer symposium in Orlando, Florida, Klotz et al. presented data from a large trial of intermittent (IADT) versus continuous androgen deprivation therapy (CADT) in the management of men with progressive prostate cancer after prior treatment with first- or second-line radiation therapy. We reported their data at the time. … READ MORE …

IAD vs. CAD all over again: are you confused yet?

New data from the randomized FinnProstate Study VII trial comparing outcomes of men randomized to treatment with either intermittent (IAD) or continuous (CAD) androgen deprivation therapy are going to further confuse physicians and patients about the relative merits of these two types of androgen deprivation therapy. … READ MORE …

Interpreting the data from the S9346/INT-0162 trial in hormone-sensitive, metastatic disease

We have already reported data, presented by Dr. Maha Hussain yesterday, that appear to show that — at least in men with clearly metastatic prostate cancer — continuous and complete androgen deprivation (CAD) extends survival significantly better than intermittent androgen deprivation (IAD). … READ MORE …

IAD vs. CAD in men with hormone-sensitive, metastatic prostate cancer

Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer. … READ MORE …

Intermittent vs. continuous androgen deprivation therapy — expert comment

A new article offers expert perspective on the relative merits of intermittent and continuous androgen deprivation therapy (ADT) in the treatment of men with metastatic prostate cancer or recurrence of disease following first- or second-line treatment. … READ MORE …